Skip to main content
. 2015 Aug 19;17(6):1483–1491. doi: 10.1208/s12248-015-9815-8

Fig. 2.

Fig. 2

The temporal course of the probabilities of experiencing a any rash intensity, b severe rash, c any diarrhea intensity, and d severe diarrhea with the administration of erlotinib (150 mg/day). Figures a, b show the attenuating effect of receiving radiotherapy prior or during treatment with erlotinib (red) in comparison to other patients (blue)